Global Bone Cement Market Size, Share & Forecast 2026-2033

Overview

The global bone cement market size was valued at USD 1.24 billion in 2025 and is projected to reach USD 1.98 billion by 2033, growing at a CAGR of 6.0% during the forecast period 2026-2033. Bone cement is a self-curing adhesive used in orthopedic and dental surgery to anchor prosthetic implants to surrounding bone; rather than acting as a true glue, it relies on mechanical interlock between the cement and the irregular bone surface to achieve fixation. Demand is rooted directly in the volume of joint replacement and spinal augmentation procedures performed worldwide, since cemented fixation remains the standard of care for a large share of hip, knee, and vertebral procedures, particularly among older patients with lower bone density who benefit from the immediate mechanical fixation that cement provides relative to press-fit, cementless alternatives.

Supply chain dynamics have become a notable feature of this market. Heraeus Medical, one of the largest global suppliers of antibiotic-loaded bone cement under its PALACOS and Refobacin brands, has faced an extended product supply shortage affecting the UK's National Health Service, prompting NHS Supply Chain to direct hospital trusts toward alternative products from Zimmer Biomet and Johnson & Johnson. North America accounted for an estimated 41% of global bone cement revenue in 2025, the largest of any region, supported by high procedure density and favorable reimbursement, while Asia-Pacific is the fastest-growing region at an estimated CAGR of approximately 8% as health-insurance coverage widens and hospital orthopedic capacity expands across China and India.

Drivers

Ageing-Related Arthroplasty Volumes Are Rising Sharply

Populations aged 65 and older are growing faster than any other demographic segment worldwide, and older adults are increasingly choosing mobility-restoring joint replacement surgery rather than living with the disability that untreated osteoarthritis or hip fracture can cause. This shift reflects improved anesthesia protocols, more durable implant designs, and value-based payment models that increasingly favor earlier surgical intervention over prolonged conservative management. Lower bone density among elderly patients makes immediate mechanical fixation, the core advantage PMMA cement offers over cementless implants, particularly valuable in this population, and longer life expectancy is simultaneously expanding the pool of patients eventually requiring revision surgery, which itself frequently requires additional cement volume.

Rising Adoption of Antibiotic-Loaded Cement Is Reinforcing Standard-of-Care Status

The escalating clinical threat of prosthetic joint infection has driven antibiotic-loaded bone cement from a specialized option toward standard-of-care status for many at-risk patients. Research published in Frontiers in Microbiology has documented that antibiotic-loaded PMMA has helped reduce prosthetic-joint infection rates from approximately 5% to under 1% over three decades of clinical use, a clinical track record that continues to expand the eligible patient base for these formulations. A Catalonia arthroplasty registry analysis published in 2025 further reinforced this evidence base, finding lower knee-revision rates among patients treated with Heraeus Medical's PALACOS antibiotic cement, and broader reimbursement acceptance, particularly in Europe, continues to accelerate clinical uptake of antibiotic-loaded formulations over plain cement.

Restraint

Growing Preference for Cementless Implants Among Younger Patients Restrains Long-Term Demand

A structural shift toward cementless, press-fit implant fixation among younger, more active patients represents a meaningful long-term restraint on bone cement demand, even as overall procedure volumes continue to climb. Cementless implants, which rely on bone growth directly into a porous or coated implant surface rather than an adhesive interlock, are increasingly preferred for younger patients with healthier bone stock who are expected to need their implant to last for several decades, since cementless fixation can simplify eventual revision surgery relative to a fully cemented implant. As implant manufacturers continue to invest in cementless technology and surgeon training shifts accordingly, this preference is expected to gradually erode bone cement's addressable market within the younger-patient segment specifically, even as the broader aging-population driver continues to support overall volume growth.

Stringent Regulatory Approval Timelines Restrain New Product Introduction

Regulatory complexity surrounding bone cement formulation changes and new product introductions represents a significant restraint on the pace of innovation in this market. Specialized FDA 510(k) pathways still require extensive bench testing data, while the European Union's Medical Device Regulation demands more extensive real-world clinical evidence than its predecessor framework, collectively delaying new product launches by as much as 18 months and adding substantial pre-market costs. These regulatory hurdles disproportionately affect smaller companies and innovative startups that lack the resources larger incumbents have to navigate increasingly complex approval processes, restraining the pace at which genuinely novel bone cement chemistries can reach surgeons and patients.

Bone Cement Market Trends & Opportunities

AI-Guided Injection Systems Are Reducing Complications and Creating a New Premium Category

The integration of artificial intelligence into cement injection and delivery systems is creating a distinct premium opportunity within this market, particularly for vertebroplasty and kyphoplasty procedures where precise cement placement directly affects both efficacy and complication risk. AI-guided injection systems that monitor real-time cement flow and pressure can meaningfully reduce leakage rates, a critical safety consideration in spinal procedures performed near neural structures, and several AI-enhanced injector developers have begun partnering directly with radiology-equipment manufacturers to embed cement delivery parameters into existing spine-navigation consoles, signaling an early but genuine shift in value from the cement material itself toward the delivery technology surrounding it.

3D-Printed Patient-Specific Spacers Represent an Emerging Customization Opportunity

The growing availability of 3D-printing technology in orthopedic and revision surgery is creating an opportunity for patient-specific cement spacers and custom fixation solutions tailored to an individual patient's bone anatomy, particularly in complex revision cases where standard implant geometries no longer fit well. This customization trend mirrors broader personalized-medicine momentum across orthopedics more generally, and companies able to combine cement formulation expertise with patient-specific design and manufacturing capability are positioned to capture a disproportionate share of the most complex, highest-value revision cases rather than competing purely on commodity cement pricing.

Outpatient Joint Replacement in Ambulatory Surgical Centres Is Reshaping Channel Strategy

The structural migration of routine hip and knee replacement procedures from hospital operating rooms into ambulatory surgical centres represents a significant channel opportunity for cement suppliers willing to tailor product packaging and formulation specifically to outpatient settings. Same-day joint replacement in ASCs can offer 40% to 60% cost savings relative to inpatient hospital procedures with comparable clinical outcomes, and policy decisions reclassifying previously inpatient-only procedures for outpatient reimbursement continue to accelerate this volume migration, raising demand specifically for fast-setting and high-viscosity cement formulations that shorten operating-room turnover time and support same-day patient discharge.

Segment Analysis

The global bone cement industry is segmented based on product type, viscosity, application, end-user, and region.

PMMA Cement Dominates the Product-Type Segment

Polymethyl methacrylate (PMMA) bone cement held a commanding share of the product-type segment in 2025, at an estimated 69%, on the strength of decades of long-term survivorship data and deep surgeon familiarity that keeps hospital procurement departments aligned with established vendors and formularies. Recent innovations within conventional PMMA chemistry, including nano-tantalum carbide doping to improve radiopacity without compromising biomechanical properties, continue to extend the segment's clinical relevance even as bioactive alternatives gain attention.

Calcium Phosphate Cement Is the Fastest-Growing Product Type

Calcium phosphate bone cement is the fastest-growing product-type segment, expanding at an estimated CAGR of approximately 6.4%, as orthopedic oncologists and trauma surgeons increasingly adopt its osteoconductive chemistry to accelerate bone integration rather than relying solely on PMMA's purely mechanical fixation. Glass polyalkenoate cements continue to find use in dental and craniofacial repair, where fluoride release offers a clinically useful secondary benefit, while calcium-sulfate-based blends serve niche infection-management applications through their resorbable properties.

Medium-Viscosity Cement Leads the Viscosity Segment

Medium-viscosity bone cement captured the leading share of the viscosity segment in 2025, at an estimated 45%, serving as the clinical workhorse for routine hip and knee arthroplasty procedures where its handling characteristics are well established and broadly familiar to surgical teams. Continued refinement within this category, including fast-setting formulations that shave several minutes off operating-room turnover time without sacrificing compressive strength, is helping medium-viscosity cement retain its central role even as higher-viscosity alternatives gain ground in spine-specific applications.

High-Viscosity Cement Is the Fastest-Growing Viscosity Category

High-viscosity bone cement is the fastest-growing viscosity category, expanding at an estimated CAGR of approximately 6.9%, supported by clinical evidence that high-viscosity formulations reduce vertebroplasty leakage rates from approximately 38% to 15% compared with lower-viscosity alternatives. Surgeons favor high-viscosity cement's dough-like handling and lower required injection pressure, which together improve operative confidence specifically in spinal procedures performed close to neural structures.

Arthroplasty Leads the Application Segment

Arthroplasty procedures accounted for the leading share of application-segment revenue in 2025, at an estimated 61%, reflecting rising acceptance of shoulder, elbow, and ankle replacement procedures in addition to the long-established base of hip and knee arthroplasty that anchors this segment's revenue. More than 53 million Americans live with some form of arthritis, a disease burden that, replicated at smaller scale across most other developed and many developing healthcare systems, sustains a deep and recurring pool of patients eligible for joint replacement surgery.

Kyphoplasty Is the Fastest-Growing Application

Kyphoplasty is the fastest-growing application segment, expanding at an estimated CAGR of approximately 6.4%, as vertebral compression fractures continue to climb alongside an aging global population. Vertebroplasty remains clinically relevant for acute spinal stabilization, though cement-volume optimization studies now generally cap infusion at roughly 40% of vertebral body capacity to avoid causing adjacent vertebral fractures, a safety consideration that is itself reinforcing demand for the higher-viscosity formulations discussed elsewhere in this report.

Regulatory Standards and Compliance Landscape

Bone cement sits at the intersection of materials science and surgical risk in a way that pulls in a denser web of standards than most single-material medical devices, spanning mechanical performance, antibiotic loading, sterilization, and ongoing post-market surveillance obligations that together shape both product development timelines and competitive entry barriers.

ISO 5833 and ASTM F451 Set the Mechanical Performance Baseline Every Formulation Must Clear

ISO 5833, "Implants for Surgery — Acrylic Resin Cements," together with its U.S. equivalent ASTM F451, defines the physical and mechanical thresholds every PMMA bone cement formulation must clear before reaching the operating room: a minimum compressive strength of 70 MPa, a minimum bending (flexural) strength of 50 MPa, and a minimum bending modulus of 1,800 MPa, alongside specified doughing-time, setting-time, and maximum curing-temperature windows. These thresholds matter commercially as much as clinically, since they define the ceiling on how much additional material, including radiopacifiers, antibiotics, or bioactive additives, a formulation can incorporate before mechanical performance is compromised.

Antibiotic Loading Forces a Direct Trade-Off Against the Same Mechanical Thresholds

Antibiotic-loaded bone cement faces a structural tension baked directly into its formulation chemistry: published research has repeatedly shown that compressive strength declines as antibiotic content rises, with some higher-dose vancomycin and gentamicin formulations approaching or falling below the ISO 5833 70 MPa threshold depending on the base cement and mixing method used. Regulatory bodies in both the United States and European Union require antibiotic-loaded formulations to demonstrate mechanical compliance under the same ISO 5833 testing protocol applied to plain cement, rather than a relaxed standard, meaning manufacturers must validate every antibiotic concentration and mixing method combination they intend to market rather than relying on bench data from a single reference formulation.

EU MDR's Post-Market Clinical Follow-Up Requirement Has Extended the Real-World Evidence Burden

The European Union's Medical Device Regulation requires manufacturers to maintain an active Post-Market Clinical Follow-up (PMCF) plan for implantable devices, including bone cement, obligating them to continuously collect real-world clinical data on long-term safety and performance rather than relying solely on pre-market trial data as was common practice under the prior Medical Device Directive. For bone cement specifically, this typically means tracking revision rates, infection rates for antibiotic-loaded variants, and any device-related adverse events across a representative patient population for years after initial CE marking, a continuous compliance cost that disproportionately affects smaller manufacturers without the registry access and clinical-affairs infrastructure that larger incumbents have already built.

Sterilization Validation Adds a Further Layer of Manufacturing-Site Compliance

Bone cement's two-component, powder-and-liquid format requires separate, validated sterilization pathways for each component, typically gamma or electron-beam irradiation for the powder component under ISO 11137 and aseptic filling or filtration-based sterilization for the liquid monomer component, since the liquid component's volatility and chemical reactivity generally preclude terminal sterilization methods such as ethylene oxide or steam autoclaving that are more commonly used elsewhere in orthopedic device manufacturing. Each sterilization method requires its own validation package and periodic revalidation under the applicable ISO 11135, 11137, or 17665 framework, adding a manufacturing-site compliance burden that runs in parallel to, rather than instead of, the product-level ISO 5833 mechanical testing already required for market access.

Geographical Penetration

North America Bone Cement Market: High Procedure Density and Reimbursement Anchor Regional Leadership

High procedure density, favorable reimbursement, and early adoption of antibiotic-rich cement blends gave the North America bone cement market the leading regional share in 2025, at an estimated 41% of global revenue.

The Centers for Medicare & Medicaid Services' 2018 decision to remove total knee arthroplasty from the inpatient-only list is reshaping the United States bone cement market specifically, a policy shift that opened the door for routine knee replacement to migrate into ambulatory surgical centres and outpatient hospital departments under bundled, site-neutral payment models; that single regulatory change continues to work its way through procurement patterns years later, pushing cement suppliers toward fast-setting, ASC-compatible packaging formats distinct from the bulk-supply contracts that still dominate inpatient hospital purchasing. The Canada bone cement market and the Mexico bone cement market round out the region, each following the broader North American shift toward bundled procedural reimbursement at a more gradual pace tied to their own provincial and national health-system structures.

Europe Bone Cement Market: Regulatory Rigor Shapes the Second-Largest Cluster

Stringent compliance requirements under the EU's Medical Device Regulation, which push suppliers to furnish more extensive real-world clinical evidence than the prior regulatory framework required, continue to shape the Europe bone cement market, the second-largest regional cluster covered in this report.

A continued clinical preference for fully cemented, rather than cementless or hybrid, fixation across a large share of hip and knee arthroplasty procedures sets the Germany bone cement market apart from several other major economies, a pattern that national arthroplasty registry data has documented for years and that keeps German per-procedure cement consumption structurally higher than markets where cementless fixation has gained more ground. An ongoing Heraeus Medical product supply shortage, which prompted the National Health Service's central supply chain to direct hospital trusts toward alternative suppliers including Zimmer Biomet and Johnson & Johnson, is actively reshaping near-term procurement patterns across the UK bone cement market into 2026. The France bone cement market, the Italy bone cement market, and the Spain bone cement market round out the largest established markets in the region, while Eastern European markets are posting comparatively faster value growth as private hospital chains continue modernizing orthopedic surgical suites.

Asia-Pacific Bone Cement Market: Fastest-Growing Region as Surgical Capacity Scales

Widening health-insurance coverage, rising osteoporosis incidence, and accelerating hospital build-outs are together making the Asia-Pacific bone cement market the fastest-growing region covered in this report, at an estimated CAGR of approximately 8% through the forecast period.

Domestic orthopedic bone cement manufacturers increasingly compete directly with multinational suppliers on cost for standard PMMA formulations across the China bone cement market, a dynamic consistent with the government's broader domestic-substitution push across medical device categories and one that is gradually narrowing the price gap between locally produced and imported cement. Japan's classification as a super-aged society, with residents aged 65 and older now representing close to 30% of the population, translates directly into one of the world's highest incidences of fragility hip fractures among elderly women specifically, sustaining outsized demand for cement-based hemiarthroplasty and fracture-fixation procedures across the Japan bone cement market relative to the country's overall population size. The India bone cement market is being shaped by the rapid expansion of private, multi-city hospital chains operating dedicated orthopedic and joint-replacement specialty centres, a corporate healthcare model that is concentrating surgical volume, and by extension cement procurement decisions, among a comparatively small number of large private operators rather than a fragmented base of independent hospitals. Well-developed healthcare systems with high per-capita orthopedic procedure volumes support steady growth across both the Australia bone cement market and the South Korea bone cement market.

Middle East and Africa Bone Cement Market: Healthcare Modernization Drives a Developing Region

Government-backed healthcare modernization programs and growing investment in specialist orthopedic surgical capacity continue to expand the GCC bone cement market, part of the broader Middle East and Africa bone cement market, while a well-developed private hospital sector continues to anchor the most organized segment of the South Africa bone cement market specifically. The rest of the region continues to build orthopedic surgical infrastructure from a comparatively early base.

South America Bone Cement Market: Brazil's Scale Anchors Regional Demand

A large domestic patient population and growing private hospital orthopedic capacity continue to anchor the Brazil bone cement market, the largest in the South America bone cement market by a clear margin, while an established hospital network and steady orthopedic procedure volumes continue to support the Argentina bone cement market, the second-largest in the region. The rest of the region continues to expand from a comparatively early base as orthopedic surgical capacity gradually scales.

Key Developments

In early 2026, Heraeus Medical experienced an extended supply shortage of its PALACOS and Refobacin bone cement product lines affecting the UK market, prompting NHS Supply Chain to direct hospital trusts toward alternative antibiotic-loaded cement products from Zimmer Biomet and Johnson & Johnson, with the disruption still being actively managed as of April 2026.

In September 2025, Stryker expanded deployment of its Mako robot-assisted surgery platform across major U.S. hospitals, reinforcing technology-enabled precision in joint-replacement procedures that rely on bone cement for implant fixation.

In July 2025, a Catalonia arthroplasty registry analysis confirmed lower knee-revision rates among patients treated with Heraeus Medical's PALACOS antibiotic-loaded bone cement, reinforcing the clinical evidence base supporting antibiotic-cement adoption.

In March 2025, Zimmer Biomet launched its Tekcem 1G and Tekcem 3G antibiotic-loaded bone cements in India for use in primary and revision arthroplasty fixation.

In April 2024, the cumulative global total of documented arthroplasty cases using Heraeus Medical's PALACOS cement crossed 40 million, marking six decades of continuous commercial availability for the product line.